GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health

SUNNYVALE, Calif., Oct. 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company wh

The S&P 500 recently sat just 2.5% below its all-time high. Look past the index, though, and the pic

SUNNYVALE, Calif., Oct. 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company wh

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 20,000 shares of the firm's stock

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report)'s stock price dropped 5.6% on Friday after an insider s

Morgan Stanley analyst Tejas Savant maintains GRAIL (NASDAQ:GRAL) with a Equal-Weight and raises

TD Cowen analyst Dan Brennan maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors headin

For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenien

Grail's stock surged after a positive FDA panel vote. Insurer adoption is crucial for Galleri's succ

Gilead Sciences (NASDAQ: GILD - Get Free Report) and GRAIL (NASDAQ: GRAL - Get Free Report) are both

Grail and Veeva Systems could be well insulated from near-term headwinds.

Jim Cramer sees three stocks with very different amounts of bad news or good news already baked into

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical

Adoption by insurers and FDA approval are critical for future performance. Profitability is not expe

UBS analyst Doug Schenkel maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target fr

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) rose 5.5% during mid-day trading on Wednesday

Guggenheim analyst Subbu Nambi maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price targ

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) hit a new 52-week high on Thursday. The compa

Grail's stock recently hit its all-time high. If the FDA approves Galleri, it still looks reasonably

The key to the company's future is medical insurers adopting Galleri. The FDA looks likely to grant

Canaccord Genuity analyst Kyle Mikson maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the pri

GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 4,100 shares of the company's st

Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price t

Grail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could dr

The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test,

Baird analyst Catherine Schulte maintains GRAIL (NASDAQ:GRAL) with a Outperform and raises the pr

Grail stock surges on favorable FDA briefing documents back its Galleri multi-cancer test ahead of t

Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular sessio

U.S. stocks rose Monday, with Nasdaq up 1%. Critical Metals jumped 38% on Greenland deal news as tec

On Wednesday, GRAIL (NASDAQ:GRAL) discussed second-quarter financial results during its earnings cal

RBC Capital analyst Dan Leonard initiates coverage on GRAIL (NASDAQ:GRAL) with a Sector Perform r

UBS analyst Doug Schenkel initiates coverage on GRAIL (NASDAQ:GRAL) with a Buy rating and announc

The FDA's advisory committee will meet on September 23 to review the PMA application for GRAIL&#

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

GRAIL (NASDAQ:GRAL) reported quarterly losses of $(2.56) per share which beat the analyst consensus

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price t

Goldman Sachs analyst Evie Koslosky initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral rati

TD Cowen analyst Dan Brennan maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target

Piper Sandler analyst David Westenberg maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises th

GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can

Wall Street analysts changed outlook on top stocks. See rating changes on NKE, SMPL, WSR, NTNX, and

Top Wall Street analysts changed outlook on top names. Initiations & upgrades noted. For full ch

Mizuho analyst Bradley Bowers initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral rating and

Piper Sandler analyst David Westenberg initiates coverage on GRAIL (NASDAQ:GRAL) with a Neutral r

GRAIL stock rises after Epic partnership expands Galleri test access; trial shows Stage IV reduction

Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within T